# Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study

> **NCT05089916** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AIO-Studien-gGmbH** · enrollment: 42 (actual)

## Conditions studied

- NSCLC
- EGFR Positive Non-small Cell Lung Cancer
- Oligoprogression

## Interventions

- **DRUG:** Osimertinib
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT05089916
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-20
- **Primary completion:** 2026-03
- **Final completion:** 2027-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05089916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05089916, "Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05089916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*